With ten years in business Coriolis has become a globally leading service provider in the field of BIOPHARMACEUTICAL DRUG DEVELOPMENT. Our service portfolio include FORMULATION DEVELOPMENT (liquid and lyophilized) for biopharmaceuticals including high concentrated and S1 / S2 classified material, LYOPHILIZATION CYCLE DEVELOPMENT, FORCED DEGRADATION STUDIES and STABILITY TESTING, COMPARABILITY STUDIES, and CONTRACT ANALYTICAL SERVICES for biopharmaceuticals (biophysical testing), (cGMP) ANALYSIS of aggregates and subvisible particles.
Coriolis offers a unique analytical service portfolio for subvisible particle analysis, troubleshooting or regulatory support. Methods include MFI, LO, RMM, AUC (including OptimaAUC) and FIELD FLOW FRACTIONATION. For gene therapy and viral based vaccine products Coriolis is equipped to support particle morphology, aggregation, size distribution, and purity analysis using e.g. AUC, TEM, NTA, and DLS.
Coriolis Pharma Research GmbH
Fraunhoferstr. 18 b
Phone: +49 89 417760-0
Fax: +49 89 417760-222
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.